https://doi.org/10.1016/j.apsb.2025.05.006
This new article publication from
Acta Pharmaceutica Sinica B, discusses high intensity forced ultrasound-driven ferroptosis as a strategy for anti-tumor immune priming.
Cold tumors have a poor response to tumor immunotherapy due to low immune cell infiltration and the ability to evade immune attacks. Converting cold tumors into hot tumors can enhance the clinical effectiveness of anti-tumor immunotherapy. High-intensity focused ultrasound (HIFU) as a non-invasive treatment can damage tumors through mechanical effects, but there is a lack of research on its cytotoxic mechanisms at the cellular level and its role in inducing anti-immune responses. In this study, the role of HIFU in triggering tumor ferroptosis by disrupting the GSH/GSSG balance through mechanochemical action and the associated anti-tumor immune priming effect were investigated. The use of a nano-enhancer loaded with PFOB combined with HIFU could enhance ferroptosis in triple-negative breast cancer at a specific stage of tumor growth (UTGR = 0) while promoting the conversion of a cold tumor into a hot tumor, thereby improving the immune response. Overall, this provides valuable guidance for the clinical application of HIFU in tumor immunotherapy.
Keywords: High intensity forced ultrasound, Perfluorooctyl bromide, Ferroptosis, GSH/GSSG balance, Triple-negative breast cancer, Tumor microenvironment, Tumor immunotherapy, Nano-enhancer
Graphical Abstract: available at
https://ars.els-cdn.com/content/image/1-s2.0-S2211383525003120-ga1_lrg.jpg
The nano-enhancer was injected into tumor-bearing mice at certain tumor growth stage. HIFU irradiation caused GSH/GSSG imbalance and triggered cell ferroptosis, activating anti-tumor immune responses, and leading to tumor regression.
# # # # # #
The Journal of the
Institute of Materia Medica, the Chinese Academy of Medical Sciences and the
Chinese Pharmaceutical Association.
For more information please visit
https://www.journals.elsevier.com/acta-pharmaceutica-sinica-b/
Editorial Board: https://www.journals.elsevier.com/acta-pharmaceutica-sinica-b/editorial-board
APSB is available on
ScienceDirect (
https://www.sciencedirect.com/journal/acta-pharmaceutica-sinica-b).
Submissions to
APSB may be made using
Editorial Manager® (
https://www.editorialmanager.com/apsb/default.aspx).
CiteScore: 24.3
Impact Factor: 14.6 (Top 6 journal in the category of Pharmacology and pharmacy)
JIF without self-citation: 13.8
ISSN 2211-3835
# # # # #
Xuejing Li, Jiayi Wu, Ruizhe Xu, Xifeng Qin, Siyu Wang, Wuli Yang, Zhiqing Pang, High intensity forced ultrasound-driven ferroptosis as a strategy for anti-tumor immune priming, Acta Pharmaceutica Sinica B, Volume 15, Issue 7, 2025, Pages 3788-3804, ISSN 2211-3835,
https://doi.org/10.1016/j.apsb.2025.05.006